In Vivo Interference of Rous Sarcoma Virus Budding by cis Expression of a WW Domain

Por Patnaik, Akash, Wills, John W.
Publicado em 2002

Ubiquitin is part of the retrovirus budding machinery

Por Patnaik, Akash, Chau, Vincent, Wills, John W.
Publicado em 2000

New strategies in Prostate Cancer: targeting lipogenic pathways and the energy sensor AMPK

Por Zadra, Giorgia, Priolo, Carmen, Patnaik, Akash, Loda, Massimo
Publicado em 2010

PI3K Enters Beta-Testing

Por Shaywitz, Adam J., Courtney, Kevin D., Patnaik, Akash, Cantley, Lewis C.
Publicado em 2008

Budding of Equine Infectious Anemia Virus Is Insensitive to Proteasome Inhibitors

Por Patnaik, Akash, Chau, Vincent, Li, Feng, Montelaro, Ronald C., Wills, John W.
Publicado em 2002

The APL Paradigm and the “Co-Clinical Trial” Project

Por Nardella, Caterina, Lunardi, Andrea, Patnaik, Akash, Cantley, Lewis C., Pandolfi, Pier Paolo
Publicado em 2011

Lysines Close to the Rous Sarcoma Virus Late Domain Critical for Budding

Por Spidel, Jared L., Craven, Rebecca C., Wilson, Carol B., Patnaik, Akash, Wang, Huating, Mansky, Louis M., Wills, John W.
Publicado em 2004

ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer

Por Gao, Shuai, Ye, Huihui, Gerrin, Sean, Wang, Hongyun, Sharma, Ankur, Chen, Sen, Patnaik, Akash, Sowalsky, Adam G., Voznesensky, Olga, Han, Wanting, Yu, Ziyang, Mostaghel, Elahe A., Nelson, Peter S., Taplin, Mary-Ellen, Balk, Steven P., Cai, Changmeng
Publicado no Clin Cancer Res (2016)

A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer

Por Lunardi, Andrea, Ala, Ugo, Epping, Mirjam T., Salmena, Leonardo, Clohessy, John G., Webster, Kaitlyn A., Wang, Guocan, Mazzucchelli, Roberta, Bianconi, Maristella, Stack, Edward C., Lis, Rosina, Patnaik, Akash, Cantley, Lewis C., Bubley, Glenn, Cordon-Cardo, Carlos, Gerald, William L., Montironi, Rodolfo, Signoretti, Sabina, Loda, Massimo, Nardella, Caterina, Pandolfi, Pier Paolo
Publicado em 2013

Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism

Por Fendt, Sarah-Maria, Bell, Eric L., Keibler, Mark A., Davidson, Shawn M., Wirth, Gregory J., Fiske, Brian, Mayers, Jared R., Schwab, Matthias, Bellinger, Gary, Csibi, Alfredo, Patnaik, Akash, Jose Blouin, Marie, Cantley, Lewis C., Guarente, Leonard, Blenis, John, Pollak, Michael N., Olumi, Aria F., Vander Heiden, Matthew G., Stephanopoulos, Gregory
Publicado em 2013

Vulnerabilities of PTEN-p53-deficient prostate cancers to compound PARP/PI3K inhibition

Por González-Billalabeitia, Enrique, Seitzer, Nina, Song, Su Jung, Song, Min Sup, Patnaik, Akash, Liu, Xue-Song, Epping, Mirjam T., Papa, Antonella, Hobbs, Robin M., Chen, Ming, Lunardi, Andrea, Ng, Christopher, Webster, Kaitlyn A., Signoretti, Sabina, Loda, Massimo, Asara, John M., Nardella, Caterina, Clohessy, John G., Cantley, Lewis C., Pandolfi, Pier Paolo
Publicado em 2014